New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function.
The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with placebo.
The results were presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting 2022.
“There is a need for us to consider cardiovascular risk when choosing type 2 diabetes medications and use treatments with a proven cardiovascular benefit in people who are at high risk,” said Dr Linda Mellbin, Karolinska Institutet, Stockholm, Sweden.
“These new analyses further reinforce the cardiovascular benefits of semaglutide in a broad range of people with type 2 diabetes.”
Most of the 6,480 adults included in these post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials had normal or mildly decreased kidney function and were normoalbuminuric.
The positive effect of semaglutide on MACE appeared to be consistent across baseline kidney function subgroups vs. placebo. When looking by baseline blood sugar, the positive effect of semaglutide on risk of MACE was also consistent.
